Thoratec (THOR) Prelim. Q2 Revenue Tops Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
Go back to Thoratec (THOR) Prelim. Q2 Revenue Tops Expectations
July 22, 2015 7:05 AM EDT
PLEASANTON, Calif., July 22, 2015 /PRNewswire/ --Â Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced preliminary unaudited revenue in the range of $128 million to $129 million for the second quarter of 2015.
"Our strong second quarter performance resulted from a broad increase in utilization of our products globally, driven in particular by favorable trends in our North American HeartMate franchise," said D. Keith Grossman, President and Chief Executive Officer. "We continued to make progress with our commercial initiatives and... More
July 22, 2015 7:00 AM EDT
Combination Accelerates Innovation-Based Growth Program and Expands
Heart Failure Franchise
St. Jude Medical Will Discuss Transaction on its Second Quarter 2015
Earnings Call Scheduled for 8 a.m. EDT (7 a.m. CDT) on July 22, 2015
ST. PAUL, Minn. & PLEASANTON, Calif.--(BUSINESS WIRE)--
St. Jude Medical (NYSE: STJ) and Thoratec (NASDAQ: THOR) today announced
that the Boards of Directors of both companies have unanimously approved
a definitive agreement under which St. Jude Medical will acquire all of
the outstanding shares of Thoratec for $63.50 per share in a... More
